XML 40 R30.htm IDEA: XBRL DOCUMENT v3.7.0.1
Acquisitions (Tables)
 3 Months Ended 12 Months Ended
Mar. 31, 2017
Dec. 31, 2016
Business Combinations [Abstract]    
Schedule of Purchase Price Allocation  
The following summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition ($ in millions):
 
2016
 
2015
 
2014
Trade accounts receivable
$
97.8

 
$
590.4

 
$
175.4

Inventories
204.8

 
521.9

 
143.5

Property, plant and equipment
161.8

 
740.0

 
82.5

Goodwill
3,061.8

 
9,841.0

 
1,492.4

Other intangible assets, primarily customer relationships, trade names and technology
1,867.0

 
5,045.3

 
1,544.4

In-process research and development
65.0

 
—

 
56.0

Trade accounts payable
(50.7
)
 
(182.0
)
 
(46.7
)
Other assets and liabilities, net
(518.0
)
 
(1,844.5
)
 
(472.6
)
Assumed debt
(1.0
)
 
(417.0
)
 
(135.5
)
Net assets acquired
4,888.5

 
14,295.1

 
2,839.4

Less: noncash consideration
(8.4
)
 
(47.3
)
 
—

Net cash consideration
$
4,880.1

 
$
14,247.8

 
$
2,839.4
Fair Values Of The Assets Acquired And Liabilities Assumed  
The following summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition for the individually significant acquisition in 2016 discussed above, and all of the other 2016 acquisitions as a group ($ in millions):
 
Cepheid
 
Others
 
Total
Trade accounts receivable
$
61.4

 
$
36.4

 
$
97.8

Inventories
165.8

 
39.0

 
204.8

Property, plant and equipment
144.5

 
17.3

 
161.8

Goodwill
2,584.0

 
477.8

 
3,061.8

Other intangible assets, primarily customer relationships, trade names and technology
1,480.0

 
387.0

 
1,867.0

In-process research and development
65.0

 
—

 
65.0

Trade accounts payable
(41.2
)
 
(9.5
)
 
(50.7
)
Other assets and liabilities, net
(452.4
)
 
(65.6
)
 
(518.0
)
Assumed debt
(1.0
)
 
—

 
(1.0
)
Net assets acquired
4,006.1

 
882.4

 
4,888.5

Less: noncash consideration
(8.4
)
 
—

 
(8.4
)
Net cash consideration
$
3,997.7

 
$
882.4

 
$
4,880.1

The following summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition for the individually significant acquisition in 2015 discussed above, and all of the other 2015 acquisitions as a group ($ in millions):
 
Pall
 
Others
 
Total
Trade accounts receivable
$
509.7

 
$
80.7

 
$
590.4

Inventories
475.5

 
46.4

 
521.9

Property, plant and equipment
713.4

 
26.6

 
740.0

Goodwill
9,556.2

 
284.8

 
9,841.0

Other intangible assets, primarily customer relationships, trade names and technology
4,798.0

 
247.3

 
5,045.3

Trade accounts payable
(155.8
)
 
(26.2
)
 
(182.0
)
Other assets and liabilities, net
(1,855.2
)
 
10.7

 
(1,844.5
)
Assumed debt
(416.9
)
 
(0.1
)
 
(417.0
)
Net assets acquired
13,624.9

 
670.2

 
14,295.1

Less: noncash consideration
(47.3
)
 
—

 
(47.3
)
Net cash consideration
$
13,577.6

 
$
670.2

 
$
14,247.8


The following summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition for the individually significant acquisition in 2014 discussed above, and all of the other 2014 acquisitions as a group ($ in millions):
 
Nobel Biocare
 
Others
 
Total
Trade accounts receivable
$
124.9

 
$
50.5

 
$
175.4

Inventories
69.0

 
74.5

 
143.5

Property, plant and equipment
59.4

 
23.1

 
82.5

Goodwill
1,013.6

 
478.8

 
1,492.4

Other intangible assets, primarily customer relationships, trade names and technology
1,049.3

 
495.1

 
1,544.4

In-process research and development
—

 
56.0

 
56.0

Trade accounts payable
(30.8
)
 
(15.9
)
 
(46.7
)
Other assets and liabilities, net
(291.0
)
 
(181.6
)
 
(472.6
)
Assumed debt
(132.7
)
 
(2.8
)
 
(135.5
)
Net cash consideration
$
1,861.7

 
$
977.7

 
$
2,839.4
Results Of Operations If Acquisition Was Consummated
The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the acquisitions been consummated as of that time ($ in millions, except per share amounts):
 
Three-Month Period Ended
 
March 31, 2017
 
April 1, 2016
Sales
$
4,205.7

 
$
4,104.5

Net earnings from continuing operations
483.8

 
550.5

Diluted net earnings per share from continuing operations
0.69

 
0.79
The unaudited pro forma information for the periods set forth below gives effect to the 2016 and 2015 acquisitions as if they had occurred as of January 1, 2015. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the acquisitions been consummated as of that time ($ in millions except per share amounts):
 
2016
 
2015
Sales
$
17,501.9

 
$
17,107.3

Net earnings from continuing operations
2,088.5

 
1,666.3

Diluted net earnings per share from continuing operations
2.99

 
2.35